Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Price Target at $4.14

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $4.14.

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Friday, January 24th. Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and raised their price objective for the company from $2.00 to $3.00 in a research report on Thursday, March 6th. Stifel Nicolaus cut their price objective on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research report on Friday, March 7th. UBS Group decreased their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a report on Monday, January 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of ALX Oncology in a research note on Friday, March 7th.

ALX Oncology Stock Down 3.2 %

Shares of NASDAQ ALXO opened at $0.52 on Wednesday. The company has a market cap of $27.54 million, a price-to-earnings ratio of -0.17 and a beta of 1.20. ALX Oncology has a 52 week low of $0.48 and a 52 week high of $17.83. The firm’s fifty day moving average is $1.00 and its 200 day moving average is $1.41. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds have recently bought and sold shares of the business. Walleye Capital LLC boosted its stake in shares of ALX Oncology by 110.3% in the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after buying an additional 121,113 shares during the last quarter. Verition Fund Management LLC increased its holdings in ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after buying an additional 100,454 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of ALX Oncology by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after acquiring an additional 22,114 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of ALX Oncology in the 3rd quarter worth $578,000. Finally, Barclays PLC raised its holdings in ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after purchasing an additional 42,185 shares during the period. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.